Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2007-07-06
2010-11-23
Chen, Stacy B (Department: 1648)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S228100
Reexamination Certificate
active
07837996
ABSTRACT:
The present invention relates to materials and methods for treatment of hepatitis C. More closely, the invention relates to human monoclonal antibodies against HCV E1 antigen, to a reagent comprising such antibodies, and to vaccine compositions comprising such antibodies. Furthermore, the invention relates to a method of treating or preventing HCV infection by administration of a vaccine composition comprising the monoclonal antibodies of the invention.
REFERENCES:
patent: 6150134 (2000-11-01), Maertens
patent: 6538114 (2003-03-01), Persson
patent: 6692908 (2004-02-01), Foung
patent: 6747136 (2004-06-01), Persson
patent: 7250166 (2007-07-01), Drakenberg et al.
patent: 2003/0180284 (2003-09-01), Foung
patent: 0947525 (1999-10-01), None
patent: 97/40176 (1997-10-01), None
patent: 00/26418 (2000-05-01), None
patent: 02/057314 (2002-07-01), None
patent: 2004/005316 (2004-01-01), None
Saadeh et al. Cleveland Clinic Journal of Medicine, 2004, vol. 71, supplement 3, pp. S3-S7.
McHutchinson et al. Hepatology, 2002, 36 :S245-252.
Berzofsky et al. The Journal of Clinical Investigation, 2004, 114(4):450-462.
Colman, P.M. Effects of amino acid sequence changes on antibody-antigen interactions, Research Immunology, Jan. 1994, vol. 145, pp. 33-36.
Bartosch, B. et al. “Infectious Hepatitis C Virus Pseudo-particles Containing Functional E1-E2 Envelope Protein Complexes”; The Journal of Experimental Medicine, 197(5): 633-642 (2003).
Hsu, M. et al. “Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles”; PNAS, 100(12): 7271-7276 (2003).
De Beeck, A.O. et al. “Characterization of Functional Hepatitis C. Virus Envelope Glycoproteins”; Journal of Virology, 78(6): 2994-3002 (2004).
Logvinoff, C. et al. “Neutralizing antibody response during acute and chronic hepatitis C virus infection”; PNAS, 101 (27): 10149-10154 (2004).
Keck, Z. et al. “Human Monoclonal Antibody to Hepatitis C Virus E1 Glycoprotein That Blocks Virus Attachment and Viral Infectivity”; Journal of Virology, 78(13): 7257-7263 (2004).
Burioni, R. et al. “Cross-reactive pseudovirus-neutralizing anti-envelope antibodies coexist with antibodies devoid of such activity in persistent hepatitis C virus infection”; Virology, 327: 242-248 (2004).
Ludwig, I.S. et al. “Hepatitis C Virus Targets DC-SIGN and L-SIGN to Escape Lysosomal Degradation”; Journal of Virology, 78(15): 8322-8332 (2004).
McKeating, J.A. et al. “Diverse Hepatitis C Virus Glycoproteins Mediate Viral Infection in a CD81-Dependent Manner”; Journal of Virology, 78(16): 8496-8505 (2004).
Taguchi, H. et al. “Antibody light chain-catalyzed hydrolysis of a hepatitis C virus peptide”; Bioorganic & Medicinal Chemistry Letters, 14: 4529-4532 (2004).
Persson, M.A., et al., “Generation of diverse high-affinity human monoclonal antibodies by repertoire cloning,” PNAS, 88:2432-2436 (Mar. 1991).
Database GENESEQP library, accession No. AAB52199, Feb. 22, 2001, retrieved from EBI.
Database GENESEQP library, accession No. AAG63656, Oct. 29, 2001, retrieved from EBI.
Database GENESEQP library, accession No. AAW13922, May 15, 1997, retrieved from EBI.
Database GENESEQP library, accession No. AAG63655, Oct. 29, 2001, retrieved from EBI.
Allander, T., et al., “Recombinant human monoclonal antibodies different conformational epitopes of the E2 envelope glycoprotein of hepatitis C virus that inhibit its interaction with CD81,” J. Gen. Virol. 81(pt. 10):2451-9, (Oct. 2000).
Drakenberg Katarina
Persson Mats A. A.
Chen Stacy B
Dann Dorfman Herrell & Skillman
Molecules of Man AB
Rigaut Kathleen D.
LandOfFree
Materials and methods for treatment of hepatitis C does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Materials and methods for treatment of hepatitis C, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Materials and methods for treatment of hepatitis C will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4200649